Updated cost-of-care estimates for commercially insured patients with multiple sclerosis: retrospective observational analysis of medical and pharmacy claims data

Cathryn A Carroll, Kathleen A Fairman, Maureen J Lage, Cathryn A Carroll, Kathleen A Fairman, Maureen J Lage

Abstract

Background: For patients with multiple sclerosis (MS), previous research identified key disease sequelae as important cost drivers and suggested that among users of disease-modifying drugs (DMDs) in 2004, DMDs represented 73% of the total cost of care. More recent studies were limited to incident disease/treatment and/or excluded DMDs from cost estimates. To support contemporary pharmacoeconomic analyses, the present study was conducted to provide updated information about MS-related costs and cost drivers including DMDs.

Methods: For each of 2 years, 2006 and 2011, commercially insured, continuously eligible patients with ≥ 1 medical claim diagnosis of MS were sampled. MS-related charges were based on medical claims with MS diagnosis plus medical/pharmacy claims for DMDs. 2006 charges were adjusted to 2011 $ using the medical care component of the consumer price index (CPI). Subgroups of patients using DMDs (interferon [IFN] beta-1a intramuscular or subcutaneous, IFN beta-1b, glatiramer, natalizumab) in 2011 were identified. By-group differences were tested with bivariate statistics.

Results: Mean (standard deviation [SD]) age of 15,902 sample patients in 2011 was 47.6 (11.8) years, 76% female. Mean [SD] MS charges ($26,520 [$38,478] overall) were significantly (P < 0.001) higher for patients with common disease sequelae: malaise/fatigue (n = 2,235; $39,948 [$48,435]), paresthesia (n = 1,566; $33,648 [$45,273]), depression (n = 1,255; $42,831 [$51,693]), and abnormality of gait (n = 1,196; $48,361 [$55,472]). From 2006 to 2011, CPI-adjusted MS charges increased by 60%. Among patients treated with a single DMD in 2011, inpatient care was 6% of charges (range = 4%-8%; P = 0.155); outpatient care was 19% (range = 14%-20% except for natalizumab [29%]; P < 0.001); and DMDs were 75% (range = 67%-81%; P < 0.001).

Conclusions: Common MS sequelae remain important cost drivers. Although MS treatment costs are increasing, the proportion of MS charges due to DMDs in 2011 is similar to that reported in 2004.

Figures

Figure 1
Figure 1
Sample selection process and cohort identification.

References

    1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000;14(13):938–952.
    1. Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. How common are the “common” neurologic disorders? Neurology. 2007;14(5):326–337.
    1. Whetten-Goldstein K, Sloan FA, Goldstein LB, Kulas ED. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler. 1998;14(5):419–425.
    1. Miller RM, Happe LE, Meyer KL, Spear RJ. Approaches to the management of agents used for the treatment of multiple sclerosis: consensus statements from a panel of U.S. managed care pharmacists and physicians. J Manag Care Pharm. 2012;14(1):54–62.
    1. Cohen JA, Rudick RA. In: Multiple Sclerosis Therapeutics. 3. Cohen JA, Rudick RA, editor. Boca Raton, FL: Taylor & Francis; 2007. Aspects of Multiple Sclerosis That Relate to Trial Design and Clinical Management; pp. 3–22.
    1. Goodin DS, Frohman EM, Garmany GP Jr, Halper J, Likosky WH, Lublin FD, Silberburg DH, Stuart WH, van den Noort S. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002;14(2):169–178.
    1. National Multiple Sclerosis Society. Expert Opinion Paper: National Clinical Advisory Board of the National Multiple Sclerosis Society. Disease Management Consensus Statement. 2008. .
    1. Goldberg LD, Edwards NC, Fincher C, Doan QV, AL-Sabbagh A, Meletiche DM. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. J Manag Care Pharm. 2009;14(7):543–555.
    1. Naci H, Fleurence R, Birt J, Duhig A. Economic burden of multiple sclerosis: a systematic review of the literature. Pharmacoeconomics. 2010;14(5):363–379.
    1. Prescott JD, Factor S, Pill M, Levi GW. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Manag Care Pharm. 2007;14(1):44–52.
    1. Pope GC, Urago CJ, Kulas ED, Kronick R, Gilmer T. Prevalence, expenditures, utilization, and payment for persons with MS in insured populations. Neurology. 2002;14(1):37–43.
    1. Bell CF. The pursuit of transparency and quality improvement in cost-effectiveness analysis: a case study in disease-modifying drugs for the treatment of multiple sclerosis. J Manag Care Pharm. 2011;14(6):463–468.
    1. Watkins JB, Sullivan SD. The payer’s dilemma: recognizing the uncertainty of clinical and economic evidence at product launch. J Manag Care Pharm. 2009;14(2):167–169.
    1. Aforismo JF, Pill MW, Prescott JD. Initiating drug therapy in multiple sclerosis. American Journal of Pharmacy Benefits. 2010;14(1):59–65.
    1. Asche CV, Singer ME, Jhaveri M, Chung H, Miller A. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States. J Manag Care Pharm. 2010;14(9):703–712.
    1. Tan H, Cai Q, Agarwal S, Stephenson JJ, Kamat S. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Adv Ther. 2011;14(1):51–61.
    1. Castelli-Haley J, Oleen-Burkey MA, Lage MJ, Johnson K. Glatiramer acetate and interferon beta-1a for intramuscular administration: a study of outcomes among multiple sclerosis intent-to-treat and persistent-use cohorts. J Med Econ. 2010;14(3):464–471.
    1. Birnbaum HG, Ivanova JI, Samuels S, Davis M, Cremieux PY, Phillips AL, Meletiche D. Economic impact of multiple sclerosis disease-modifying drugs in an employed population: direct and indirect costs. Curr Med Res Opin. 2009;14(4):869–877.
    1. Curkendall SM, Wang C, Johnson BH, Cao Z, Preblick R, Torres AM, Knappertz V, Gondek K. Potential health care cost savings associated with early treatment of multiple sclerosis using disease-modifying therapy. Clin Ther. 2011;14(7):914–925.
    1. Ivanova JI, Bergman RE, Birnbaum HG, Phillips AL, Stewart M, Meletiche DM. Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US. J Med Econ. 2012;14(3):601–609.
    1. Trisolini MG. Comparison of Multiple Sclerosis Guidelines Underscores Need for Collaboration. U.S. Department of Health and Human Services, National Guideline Clearinghouse; 2008. .
    1. U.S. Department of Health and Human Services, National Guideline Clearinghouse. Guidelines by Topic: Multiple Sclerosis. [ +sclerosis]
    1. U.S. Food and Drug Administration. Important new Information – on Natalizumab (Marketed as Tysabri) 2006. .
    1. U.S. Food and Drug Administration. FDA News Release. FDA Approves Resumed Marketing of Tysabri Under a Special Distribution Program. 2006. (updated June 6, 2006) .
    1. U.S. Food and Drug Administration. Center Watch. Extavia (interferon beta 1-b) [ ]
    1. Hawton A, Shearer J, Goodwin E, Green C. Squinting through layers of fog: assessing the cost effectiveness of treatments for multiple sclerosis. Appl Health Econ Health Policy. 2013;14(4):331–341.
    1. Weinstein MC, O’Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, Luce BR. ISPOR Task Force of Good Research Practices—Modeling Studies. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR task force on good research practices—modeling studies. Value Health. 2003;14(1):9–17.
    1. Schafer JA, Gunderson BW, Gleason PP. Price increases and new drugs drive increased expenditures for multiple sclerosis. J Manag Care Pharm. 2010;14(9):713–717.
    1. U.S. Food and Drug Administration. FDA Drug Safety Communication: New Risk Factor for Progressive Multifocal Leukoencephalopathy (PML) Associated With Tysabri (Natalizumab) 2012. .
    1. U.S. Food and Drug Administration. Risk Evaluation and Mitigation Strategy (REMS). Tysabri Outreach. Unified Commitment to Health (TOUCH®) Prescribing Program (MS & CD) .

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi